Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis: a synopsis of MS-STAT2, a multicentre, randomised controlled, double-blind, phase 3 clinical trial
Background Despite the relative success of immuno-modulatory disease-modifying therapy in relapsing remitting multiple sclerosis, progressive worsening of disability remains a major problem, particularly for those with secondary progressive multiple sclerosis. Various underlying mechanisms are likel...
Сохранить в:
| Главные авторы: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
NIHR Journals Library
2026-06-01
|
| Серии: | Health Technology Assessment |
| Предметы: | |
| Online-ссылка: | https://doi.org/10.3310/GJJC5820 |
| Метки: |
Нет меток, Требуется 1-ая метка записи!
|
